Dr Tsoli has a PhD in Cancer Cell Biology and Molecular Modelling, in which she examined the anticancer potential of gold-based nanoparticles. She subsequently accepted postdoctoral positions at the ANZAC Research Institute/USYD and Sanford-Burnham Institute/USA where she focused on elucidating signalling pathways involved in the development of cancer cachexia syndrome (CCS) and paediatric bone disorder hypophosphatasia. She is currently leading the Brain Tumour Group at the Children’s Cancer Institute (CCI) under the mentorship of A/Prof Ziegler. She is the lead scientist responsible for establishing state of the art techniques for research in Diffuse Intrinsic Pontine Gliomas (DIPG) and the development of glioma PDX models as part of the national PRecISion Medicine for Children with Cancer trial (PRISM). Key achievements include the (a) establishment of primary brain tumour neurospheres (DIPG, glioblastoma, medulloblastoma) and orthotopic animal models from paediatric overseas and Australian patient’s biopsies/ autopsies; and (b) establishment of single-agent and combination high-throughput screening performed on primary DIPG neurosphere-forming cells. Dr Tsoli is also responsible for the research direction of multiple DIPG projects, laboratory management, and is committed to developing the expertise and careers of junior research staff in the program exhibited by her supervision of research staff (currently 1 PhD student, 5 research assistants and 3 postdocs).
2020: Senior Lecturer (Conjoint)
2019: Levi Wheeler Fellow
2016: Organisation of Hellene and Hellene-Cypriot Women of Australia
2013: Children's Cancer Institute Quarterly Staff award
1. Levi's Project: A future for kids with DIPG. Development of a preclinical multimodal therapy protocol for Diffuse Midline Gliomas.
2. Evaluation of the blood-brain-barrier (BBB) function in the presence of high-grade gliomas and development of approaches to influence it's permeability.
3. Development of personalised therapies and paediatric brain tumour PDX models from biopsies and autopsies.
4. Targeting the polyamine pathway as a therapeutic approach for the treatment of aggressive paediatric brain tumours.
5. High throughput drug screening approaches to find new treatments for Diffuse Midline Gliomas.